Session 2-2-E: Slots are to Las Vegas as Baccarat is to Macau: A Game Analysis

Money is reeling in the casinos in Las Vegas, while chips are rolling in the casinos in Macau. These two different phrases exactly symbolize the ways how these two different gaming jurisdictions make their prosperity. There are several reels in the slot machines and as they are spun thousands and millions of times…money reels in, it creates the profit for the casinos in Las Vegas. Baccarat players wager dead chips in the VIP rooms rolling thousands and millions of times…money rolls in, it creates the profit for the casinos in Macau

Miniaturized Resonator and Bandpass Filter for Silicon-Based Monolithic Microwave and Millimeter-Wave Integrated Circuits

© 2018 IEEE. © 2018 IEEE. Personal use is permitted, but republication/redistribution requires IEEE permission.This paper introduces a unique approach for the implementation of a miniaturized on-chip resonator and its application for the first-order bandpass filter (BPF) design. This approach utilizes a combination of a broadside-coupling technique and a split-ring structure. To fully understand the principle behind it, simplified LC equivalent-circuit models are provided. By analyzing these models, guidelines for implementation of an ultra-compact resonator and a BPF are given. To further demonstrate the feasibility of using this approach in practice, both the implemented resonator and the filter are fabricated in a standard 0.13-μm (Bi)-CMOS technology. The measured results show that the resonator can generate a resonance at 66.75 GHz, while the BPF has a center frequency at 40 GHz and an insertion loss of 1.7 dB. The chip size of both the resonator and the BPF, excluding the pads, is only 0.012mm 2 (0.08 × 0.144 mm 2).Peer reviewe

Crystallization and preliminary crystallographic analysis of the central domain of Drosophila Dribble, a protein that is essential for ribosome biogenesis. Addendum

An addition to the paper by Cheng et al. [(2010), Acta Cryst. F66, 546–548]

An Ultra-Wideband Circularly Polarized Asymmetric-S Antenna With Enhanced Bandwidth and Beamwidth Performance

This paper introduces an ultra-wideband circularly polarized (CP) asymmetric-S antenna with wide axial ratio beamwidth (ARBW) for C-band applications. The proposed antenna is realized by bending a linearly polarized dipole into asymmetric-S shape with variable trace width, which achieves CP radiation. Unlike the reported symmetric-S antenna, the proposed antenna is constituted with two unequal curved arms to enhance the bandwidth and beamwidth performances. Compared with the symmetric-S antenna, the proposed antenna demonstrates much wider AR bandwidth and wider ARBW over broader frequency range. A prototype is fabricated to verify the design principle. The measured and simulated results are very consistent and both indicate that the proposed antenna has a wide impedance bandwidth (VSWR <; 2) of 70.2% (3.58 to 7.46 GHz), and a wide 3-dB AR bandwidth of 84.8% (2.75 to 6.8 GHz). Moreover, maximum ARBW of 153° is achieved, and a 3-dB ARBW of more than 100° is maintained within a wide operation bandwidth of 46.3% (3.65-5.85 GHz)

Restoring Hong Kong's landscar in the Anderson Quarry : an analysis of civic engagement strategies

published_or_final_versionPolitics and Public AdministrationMasterMaster of Public Administratio

A Differential Broadband Dual-Polarized Base Station Antenna Element for 4G And 5G Applications

In this paper, a broadband differential feed ±45° dual-polarized base station antenna element is proposed for 4G and 5G mobile communications. The proposed antenna consists of two orthogonally placed dipoles, square patch and reflector, where each dipole adds six elliptical branches to broaden the bandwidth. Simulation results show that the proposed antenna element has the impedance bandwidth of 65% (1.84-3.6 GHz) within the operating frequency (S11 <; -15 dB and S21 <; -21 dB), and good radiation characteristics and high cross polarization ratio are also achieved

Protective effects and potential mechanisms of Pien Tze Huang on cerebral chronic ischemia and hypertensive stroke

<p>Abstract</p> <p>Background</p> <p>Stroke caused by brain ischemia is the third leading cause of adult disability. Active prevention and early treatment of stroke targeting the causes and risk factors may decrease its incidence, mortality and subsequent disability. Pien Tze Huang (PZH), a Chinese medicine formula, was found to have anti-edema, anti-inflammatory and anti-thrombotic effects that can prevent brain damage. This study aims to investigate the potential mechanisms of the preventive effects of Pien Tze Huang on brain damage caused by chronic ischemia and hypertensive stroke in rats.</p> <p>Methods</p> <p>The effects of Pien Tze Huang on brain protein expression in spontaneously hypertensive rat (SHR) and stroke prone SHR (SHRsp) were studied with 2-D gel electrophoresis and mass spectrometric analysis with a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF)/TOF tandem mass spectrometer and on brain cell death with enzyme link immunosorbent assay (ELISA) and immunostaining.</p> <p>Results</p> <p>Pien Tze Huang decreased cell death in hippocampus and cerebellum caused by chronic ischemia and hypertensive stroke. Immunostaining of caspase-3 results indicated that Pien Tze Huang prevents brain cells from apoptosis caused by ischemia. Brain protein expression results suggested that Pien Tze Huang downregulated QCR₂in the electron transfer chain of mitochondria preventing reactive oxygen species (ROS) damage and possibly subsequent cell death (caspase 3 assay) as caused by chronic ischemia or hypertensive stroke to hippocampus and cerebellum.</p> <p>Conclusion</p> <p>Pien Tze Huang showed preventive effects on limiting the damage or injury caused by chronic ischemia and hypertensive stroke in rats. The effect of Pien Tze Huang was possibly related to prevention of cell death from apoptosis or ROS/oxidative damage in mitochondria.</p

Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users

Aims This study aimed to compare the rates of major cardiovascular adverse events in sodium-glucose cotransporter-2 inhibitors (SGLT2I) and dipeptidyl peptidase-4 inhibitors (DPP4I) users in a Chinese population. SGLT2I and DPP4I are increasingly prescribed for type 2 diabetes mellitus patients. However, few population-based studies are comparing their effects on incident heart failure or myocardial infarction. Methods and results This was a population-based retrospective cohort study using the electronic health record database in Hong Kong, including type 2 diabetes mellitus patients receiving either SGLT2I or DPP4I from 1 January 2015 to 31 December 2020. Propensity score matching was performed in a 1:1 ratio based on demographics, past comorbidities, and non-SGLT2I/DPP4I medications with nearest neighbour matching (caliper = 0.1). Univariable and multivariable Cox models were used to identify significant predictors for new-onset heart failure, new-onset myocardial infarction, cardiovascular mortality, and all-cause mortality. Sensitivity analyses with competing risk models and multiple propensity score matching approaches were conducted. A total of 41 994 patients (58.89% males, median admission age at 58 years old, interquartile range [IQR]: 51.2–65.3) were included with a median follow-up of 5.6 years (IQR: 5.32–5.82). In the matched cohort, SGLT2I use was significantly associated with lower risks of new-onset heart failure (hazard ratio [HR]: 0.73, 95% confidence interval [CI]: [0.66, 0.81], P < 0.0001), myocardial infarction (HR: 0.81, 95% CI: [0.73, 0.90], P < 0.0001), cardiovascular mortality (HR: 0.67, 95% CI: [0.53, 0.84], P < 0.001), and all-cause mortality (HR: 0.26, 95% CI: [0.24, 0.29], P < 0.0001) after adjusting for significant demographics, past comorbidities, and non-SGLT2I/DPP4I medications. Conclusions SGLT2 inhibitors are protective against adverse cardiovascular events including new-onset heart failure, myocardial infarction, cardiovascular mortality, and all-cause mortality. The prescription of SGLT2I is preferred when taken into consideration individual cardiovascular and metabolic risk profiles in addition to drug–drug interactions